[1] World Health Organization. Polio vaccines: WHO position paper, March 2016-recommendations. Vaccine 2017;35(9):1197 − 9. https://doi.org/10.1016/j.vaccine.2016.11.017CrossRef
[2] Burns CC, Diop OM, Sutter RW, Kew OM. Vaccine-derived polioviruses. J Infect Dis 2014;210 Suppl 1:S283-93. http://dx.doi.org/10.1093/infdis/jiu295.
[3] Sutter RW, Cochi SL. Inactivated poliovirus vaccine supply shortage: is there light at the end of the tunnel? J Infect Dis 2019;220(10):1545-6. http://dx.doi.org/10.1093/infdis/jiy739.
[4] Shi HY, Liao GY, Che YC, Yi L, Yang YF, Li JX, et al. Advances in development and application of inactivated poliomyelitis vaccine made from Sabin strain. Chin J Biologicals 2022;35(8):897 − 906. https://doi.org/10.13200/j.cnki.cjb.003687CrossRef
[5] Yu WZ, Jiang Y, Cong B, Zhang SY, Ji SS, Liu J, et al. A baseline survey of guardian’s awareness of introducing inactivated poliovirus vaccine into the national immunization program pilot provinces. Chin J Vaccines Immun 2016;22(5):487 − 92. https://doi.org/10.19914/j.cjvi.2016.05.002CrossRef
[6] Wang SQ, Zhang C, Wang L, Zhao MJ. Suspected adverse events following immunization of poliomyelitis vaccines in Hubei province: analysis on surveillance data of 2015–2017. Chin J Public Health 2018;34(5):736 − 40. https://doi.org/10.11847/zgggws1118771CrossRef
[7] National Health Commission, Ministry of Finance, Ministry of Industry and Information Technology, National Medical Products Administration. Notice on the adjustment of the immunization schedule of the national immunization program for polio vaccine and measles-containing vaccine. Bulletin of the National Health Commission of the People’s Republic of China 2019(12):25-6. http://www.nhc.gov.cn/bgt/201812v/202003/7c2b85ecaf1b4f76ab6b69fddf1e5ebf.shtml. [2023-5-26]. (In Chinese)
[8] China Ministry of Health, Food and Drug Administration of China. National guideline for the surveillance of adverse events following immunization. Chin J Vaccines Immun 2011;17(1):72-81. http://www.nhc.gov.cn/jkj/wslgf/201402/5dd5633d93174a7c8e93d8af7579a613.shtml.
[9] Health Resources & Services Administration. Vaccine injury table. https://www.hrsa.gov/sites/default/files/hrsa/vicp/vaccine-injury-table-01-03-2022.pdf. [2024-4-18].
[10] Kang GD, Tang FY, Wang ZG, Hu R, Yu J, Gao J. Surveillance of adverse events following the introduction of inactivated poliovirus vaccine made from Sabin strains (sIPV) to the Chinese EPI and a comparison with adverse events following inactivated poliovirus vaccine made from wild strains (wIPV) in Jiangsu, China. Hum Vaccin Immunother 2021;17(8):2568 − 74. https://doi.org/10.1080/21645515.2021.1898306CrossRef
[11] Fu SM, Lin L, Cao FR, Tian X, Cheng T, Chen C, et al. Comparison of immunization safety of 4 kinds of polio vaccines in Jilin province. Chin J Vaccines Immun 2017;23(4):379 − 82,374. https://doi.org/10.19914/j.cjvi.2017.04.005CrossRef
[12] Shi XH, Zhou LP, Zhou LW, Liu L. Safety of domestic Sabin strain inactivated poliovirus vaccine. Chin J Vaccines Immun 2017;23(4):383 − 6. https://doi.org/10.19914/j.cjvi.2017.04.006CrossRef
[13] Chu K, Ying ZF, Wang L, Hu YS, Xia JL, Chen L, et al. Safety and immunogenicity of inactivated poliovirus vaccine made from Sabin strains: a phase II, randomized, dose-finding trial. Vaccine 2018;36(45):6782 − 9. https://doi.org/10.1016/j.vaccine.2018.09.023CrossRef
[14] Hu YM, Xu KW, Han WX, Chu K, Jiang DY, Wang JF, et al. Safety and immunogenicity of Sabin strain inactivated poliovirus vaccine compared with Salk strain inactivated poliovirus vaccine, in different sequential schedules with bivalent oral poliovirus vaccine: randomized controlled noninferiority clinical trials in China. Open Forum Infect Dis 2019;6(10):ofz380. https://doi.org/10.1093/ofid/ofz380CrossRef
[15] Zhang LN, Li KL, Du W, Li Y, Fan CX, Yu WZ, et al. Surveillance of adverse events following immunization in China, 2019. Chin J Vaccines Immun 2021;27(4):438 − 45. https://doi.org/10.19914/j.CJVI.2021075CrossRef
[16] Fu YT, Liu XC, Zhao T, Yang JS. Advances in poliomyelitis immunization strategies and vaccine supply. Chin J Biologicals 2019;32(5):584 − 8,593. https://doi.org/10.13200/j.cnki.cjb.002621CrossRef
[17] Wang JF, Ying ZF, Xu KW, Jiang Z, Li CG. Summary and quality analysis of batch issuance of inactivated polio vaccine in 2009–2016. Chin J Biologicals 2018;31(1):97-9,105. http://dx.doi.org/10.13200/j.cnki.cjb.002063. (In Chinese)